Wounds - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 209
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W00F0C8433BEN
Leaflet:

Download PDF Leaflet

Wounds - Pipeline Review, H2 2017
Wounds - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H2 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/organs caused by surgery, a blow, a cut, chemicals, heat/cold, friction/shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 8, 1, 56, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 6 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Wounds - Overview
Wounds - Therapeutics Development
Wounds - Therapeutics Assessment
Wounds - Companies Involved in Therapeutics Development
Wounds - Drug Profiles
Wounds - Dormant Projects
Wounds - Discontinued Products
Wounds - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Wounds, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Wounds - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017
Wounds - Pipeline by AlgiPharma AS, H2 2017
Wounds - Pipeline by Alliance Pharma Plc, H2 2017
Wounds - Pipeline by AmpliPhi Biosciences Corp, H2 2017
Wounds - Pipeline by AndroScience Corp, H2 2017
Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Wounds - Pipeline by Beech Tree Labs Inc, H2 2017
Wounds - Pipeline by Bioblue Technologies Inc, H2 2017
Wounds - Pipeline by Biotec Pharmacon ASA, H2 2017
Wounds - Pipeline by Cellphire Inc, H2 2017
Wounds - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Wounds - Pipeline by CorMedix Inc, H2 2017
Wounds - Pipeline by CytoTools AG, H2 2017
Wounds - Pipeline by Dermala Inc, H2 2017
Wounds - Pipeline by Destiny Pharma Ltd, H2 2017
Wounds - Pipeline by Escape Therapeutics Inc, H2 2017
Wounds - Pipeline by Exicure Inc, H2 2017
Wounds - Pipeline by Exogenus Therapeutics SA, H2 2017
Wounds - Pipeline by FibroGen Inc, H2 2017
Wounds - Pipeline by Gene Signal International SA, H2 2017
Wounds - Pipeline by GlaxoSmithKline Plc, H2 2017
Wounds - Pipeline by IC-MedTech Inc, H2 2017
Wounds - Pipeline by Living Cell Technologies Ltd, H2 2017
Wounds - Pipeline by Madam Therapeutics BV, H2 2017
Wounds - Pipeline by MediWound Ltd, H2 2017
Wounds - Pipeline by Miragen Therapeutics Inc, H2 2017
Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H2 2017
Wounds - Pipeline by Nippon Chemiphar Co Ltd, H2 2017
Wounds - Pipeline by Novan Inc, H2 2017
Wounds - Pipeline by Octapharma AG, H2 2017
Wounds - Pipeline by Omeros Corp, H2 2017
Wounds - Pipeline by Osiris Therapeutics Inc, H2 2017
Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H2 2017
Wounds - Pipeline by ProMetic Life Sciences Inc, H2 2017
Wounds - Pipeline by SomaGenics Inc, H2 2017
Wounds - Pipeline by Stratatech Corp, H2 2017
Wounds - Pipeline by Synedgen Inc, H2 2017
Wounds - Pipeline by Thesan Pharmaceuticals Inc, H2 2017
Wounds - Pipeline by Topadur Pharma AG, H2 2017
Wounds - Pipeline by Traverse Biosciences Inc, H2 2017
Wounds - Pipeline by Tumorend LLC, H2 2017
Wounds - Pipeline by Vascular BioSciences, H2 2017
Wounds - Pipeline by viDA Therapeutics Inc, H2 2017
Wounds - Dormant Projects, H2 2017
Wounds - Dormant Projects, H2 2017 (Contd.1), H2 2017
Wounds - Dormant Projects, H2 2017 (Contd.2), H2 2017
Wounds - Dormant Projects, H2 2017 (Contd.3), H2 2017
Wounds - Dormant Projects, H2 2017 (Contd.4), H2 2017
Wounds - Dormant Projects, H2 2017 (Contd.5), H2 2017
Wounds - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Wounds, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Advanced Inhalation Therapies (AIT) Ltd
AlgiPharma AS
Alliance Pharma Plc
AmpliPhi Biosciences Corp
AndroScience Corp
Aridis Pharmaceuticals LLC
Beech Tree Labs Inc
Bioblue Technologies Inc
Biotec Pharmacon ASA
Cellphire Inc
Chiesi Farmaceutici SpA
CorMedix Inc
CytoTools AG
Dermala Inc
Destiny Pharma Ltd
Escape Therapeutics Inc
Exicure Inc
Exogenus Therapeutics SA
FibroGen Inc
Gene Signal International SA
GlaxoSmithKline Plc
IC-MedTech Inc
Living Cell Technologies Ltd
Madam Therapeutics BV
MediWound Ltd
Miragen Therapeutics Inc
NatureWise Biotech & Medicals Corp
Nippon Chemiphar Co Ltd
Novan Inc
Octapharma AG
Omeros Corp
Osiris Therapeutics Inc
Pacific Northwest Biotechnology LLC
ProMetic Life Sciences Inc
SomaGenics Inc
Stratatech Corp
Synedgen Inc
Thesan Pharmaceuticals Inc
Topadur Pharma AG
Traverse Biosciences Inc
Tumorend LLC
Vascular BioSciences
viDA Therapeutics Inc
Skip to top


Ask Your Question

Wounds - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: